$BCRX News

JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price Target

BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

RBC Capital Maintains Outperform on BioCryst Pharma, Raises Price Target to $14

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target

Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29

BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47M

BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level

BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharma To Present Seven Abstracts From Hereditary Angioedema Portfolio At Annual Meeting Of EAACI 2026

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals To Present New Real-World Evidence At The International Society For Pharmacoeconomics And Outcomes Research Conference, May 17–20